0.52
전일 마감가:
$0.55
열려 있는:
$0.55
하루 거래량:
1.40M
Relative Volume:
0.10
시가총액:
$62.38M
수익:
-
순이익/손실:
$-225.14M
주가수익비율:
-0.2653
EPS:
-1.96
순현금흐름:
$-192.27M
1주 성능:
-13.33%
1개월 성능:
-50.48%
6개월 성능:
-45.29%
1년 성능:
-85.47%
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
1601 TRAPELO ROAD, WALTHAM
IVVD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IVVD
Invivyd Inc
|
0.52 | 62.38M | 0 | -225.14M | -192.27M | -1.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2023-05-01 | 개시 | H.C. Wainwright | Buy |
Invivyd Inc 주식(IVVD)의 최신 뉴스
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd Appoints Ajay Royan to its Board of Directors - citybiz
Invivyd adds venture capitalist Ajay Royan to board By Investing.com - Investing.com South Africa
Invivyd Appoints Ajay Royan to Board of Directors - TipRanks
Invivyd adds venture capitalist Ajay Royan to board - Investing.com India
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - The Manila Times
Major Investor Takes Board Seat: Invivyd Eyes Breakthrough Beyond COVID-19 Treatment - Stock Titan
Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital - Defense World
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - MSN
INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI - Business Wire
Invivyd Reports Strong Revenue Growth and Promising Developments - TipRanks
Invivyd earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 20, 2025 at 08:12 am EDT - MarketScreener
Invivyd, Inc. SEC 10-K Report - TradingView
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 - Nasdaq
Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates - Nasdaq
Invivyd (IVVD) Projected to Post Earnings on Thursday - Defense World
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 - Investing.com India
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - The Manila Times
Invivyd's COVID Treatment Still Works Against Elusive LP.8.1 VariantCritical News for Immunocompromised Patients - StockTitan
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody - Simply Wall St
Invivyd Inc [IVVD] Insider Activity: An Update for Investors - Knox Daily
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Armenian Reporter
The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital - Defense World
Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright - Defense World
FDA declines Invivyd's COVID-19 treatment EUA expansion By Investing.com - Investing.com Australia
FDA declines Invivyd’s COVID-19 treatment EUA expansion By Investing.com - Investing.com Nigeria
IVVD Stock: More Upside For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - TradingView
Invivyd says FDA declines request to expand existing EUA of PEMGARDA - TipRanks
Sector Update: Health Care - TradingView
5 Stocks That More Than Doubled Halfway Through Q1 - Zacks Investment Research
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
Invivyd shares drop as FDA declines company's COVID-19 treatment EUA expansion - MSN
FDA declines Invivyd’s COVID-19 treatment EUA expansion - Investing.com India
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Chang - The Manila Times
Can PEMGARDA Still Succeed? FDA Blocks COVID Treatment Expansion but Keeps Prevention Approval - StockTitan
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January - Armenian Reporter
Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far - MSN
10 Micro and Small-Cap Firms Drive Year-to-Date Gains - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest - MarketBeat
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Invivyd Inc 주식 (IVVD) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
자본화:
|
볼륨(24시간):